Effects of sodium-glucose cotransporter-2 inhibitors on serum urate levels and gout in patients with and without type 2 diabetes: a systematic review and network meta-analysis
Authors:
- 2 July 2025
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 47 (5) , 1162-1176
Abstract
Background Sodium-glucose cotransporter-2 (SGLT-2) inhibitors can decrease serum uric acid (sUA) levels and have potential in the management of glucose levels and cardiorenal protection in patients. Aim This systematic review and network meta-analysis aimed to investigate the effects of SGLT-2 inhibitors on sUA levels and incidence of gout in patients with or without type 2 diabetes. Method A systematic search of PubMed, Embase, Cochrane Central Register of Controlled Trials, and Clinical Trials databases was performed to retrieve relevant articles published from inception to April 27, 2025, focusing on the impact of SGLT-2 inhibitors on sUA levels or the incidence of gout in the study participants. We performed a Bayesian random-effects network meta-analysis of the included studies using the Markov Chain Monte Carlo simulation techniques. The grading of recommendations, assessment, development, and evaluation approach was used to assess the certainty of the evidence. Results A total of 57 trials were included. All SGLT-2 inhibitors reduced sUA levels. These inhibitors demonstrated a spectrum of sUA-lowering effects, with empagliflozin and dapagliflozin exhibiting particularly robust efficacy. Specifically, empagliflozin (10 mg: − 43 [95% CI − 52.45 to − 33.66]; 25 mg: − 41.99 [95% CI − 51.93 to − 31.9]; 50 mg: − 35.77 [95% CI − 68.04 to − 3.53]) and dapagliflozin (5 mg: − 36.91 [95% CI − 49.5 to − 24.46]; 10 mg: − 34.98 [95% CI − 43.75 to − 26.44]) displayed superior reductions in sUA levels compared to other agents within the class. Although there was a potential reduction in the incidence of gout associated with SGLT-2 inhibitors, the difference was not statistically significant. Conclusion Future long-term studies should consider SGLT-2 inhibitors for individuals requiring sUA reduction and gout management. These results could serve as a reference for future guidelines addressing the treatment of individuals with diabetes, necessitating sUA lowering and gout management. Trial Registration PROSPERO registration number CRD42024521695.Keywords
Funding Information
- Sichuan Provincial Science and Technology Support Program (2023JDR0243)
- Health Commission Program (2020-111)
- Sichuan Science and Technology Support Program (2023NSFSC1696)
This publication has 86 references indexed in Scilit:
- Gout and sodium‐glucose cotransporter‐2 inhibitorsPharmacoepidemiology and Drug Safety, 2021
- Empagliflozin Confers Reno-Protection in Acute Myocardial Infarction and Type 2 Diabetes MellitusESC Heart Failure, 2021
- Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trialDiabetology International, 2021
- 2020 American College of Rheumatology Guideline for the Management of GoutArthritis Care & Research, 2020
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled studyDiabetologia, 2018
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaBiopharmaceutics & Drug Disposition, 2014
- Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II TrialAdvances in Therapy, 2014
- Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN studyDiabetology International, 2014
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trialArthritis Care & Research, 2008